Diadexus, Inc. to Report Second Quarter 2015 Financial Results on August 13, 2015

Diadexus, Inc. to Report Second Quarter 2015 Financial Results on August 13, 2015

ID: 412073

Conference Call and Webcast Scheduled for 4:30 p.m. ET (1:30 p.m. PT)


(firmenpresse) - SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 08/06/15 -- Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced that it will report second quarter 2015 financial results on Thursday, August 13, 2015 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 p.m. ET (1:30 p.m. PT).

To access the webcast, visit the Company's website at . To access the conference call, dial (855) 666-6874 for domestic callers and (262) 912-6259 for international callers. The reservation number for both is 93519113. A replay of the webcast will be available shortly following the live webcast for a period of four weeks.



Diadexus, based in South San Francisco, California, is a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, providing healthcare providers with actionable information for managing patients. The Company pioneered the testing of Lp-PLA2 (lipoprotein-associated phospholipase A2), a marker of vascular-specific inflammation that provides new information, over and above traditional risk factors measured in a lipid panel, and has over a decade of peer-reviewed literature validating its utility. Diadexus' products, The PLAC® Test ELISA Kit, first cleared by the FDA in 2003, and The PLAC® Test for Lp-PLA2 Activity, cleared in December 2014, are the only two FDA-cleared tests to measure Lp-PLA2.

The Company also has a pipeline of biomarkers for heart failure, proADM, proET-1 and proANP, with each providing distinct, additive information for healthcare providers over currently available markers. Diadexus also provides services to pharmaceutical partners to address the need to incorporate biomarkers in clinical development. For more information, please visit the Company's website at .



CONTACT:





Leone Patterson
650-246-6432
Chief Financial Officer


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Ritter Pharmaceuticals Retains William M. Merino as Senior Clinical and Regulatory Advisor Bio-Rad Reports Second-Quarter 2015 Financial Results
Bereitgestellt von Benutzer: Marketwired
Datum: 06.08.2015 - 13:15 Uhr
Sprache: Deutsch
News-ID 412073
Anzahl Zeichen: 0

contact information:
Town:

SOUTH SAN FRANCISCO, CA



Kategorie:

Healthcare



Diese Pressemitteilung wurde bisher 173 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Diadexus, Inc. to Report Second Quarter 2015 Financial Results on August 13, 2015"
steht unter der journalistisch-redaktionellen Verantwortung von

Diadexus, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Diadexus, Inc. to File Chapter 7 ...

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 06/10/16 -- Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in assessing the prognosis of cardiac disease, today announced that it is filing for relief ...

Diadexus, Inc. Reports First Quarter 2016 Financial Results ...

SOUTH SAN FRANCISCO, CA -- (Marketwired) -- 04/28/16 -- Diadexus, Inc. (OTCQB: DDXS), a diagnostics company developing and commercializing products that aid in the prediction of cardiac disease risk, today announced financial results for the first q ...

Alle Meldungen von Diadexus, Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z